1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Biostock publishes an article after Prolight published its Year-End Report for 2025

Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026, Prolight is firmly setting its sights on a commercial launch in 2027. 

Read the full article here: https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Biostock publishes an article after Prolight published its Year-End Report for 2025

Datum 2026-03-03, kl 08:15
Källa MFN
Bifogade filer
Biostock publishes an article after Prolight published its Year-End Report for 2025